Molecular Therapy · 2013 · 129 citations · 43 references
PharmacyNeurobiologyNeuroscienceGene DeliveryGene TherapyMolecular NeuroscienceAxonal TransportCentral Nervous SystemGene Delivery VectorsIn Vivo Gene DeliveryNeurological Gene TherapySystemic Gene DeliveryMuscle Gene DeliveryMuscle Gene TherapyNeuromuscular Gene TherapyNeuronal Gene TransferNucleic Acid Delivery To The Central Nervous SystemRetrograde Axonal TransportSpinal Cord Gene TherapyViral Vector Delivery
We have recently demonstrated the remarkable efficiency of self-complementary (sc) AAV9 vectors for central nervous system (CNS) gene transfer following intravenous delivery in mice and larger animals. Here, we investigated whether gene delivery to motor neurons (MNs) could also be achieved via intramuscular (i.m.) scAAV9 injection and subsequent retrograde transport along the MNs axons. Unexpectedly, we found that a single injection of scAAV9 into the adult mouse gastrocnemius (GA) mediated widespread MN transduction along the whole spinal cord, without limitation to the MNs connected to the injected muscle. Spinal cord astrocytes and peripheral organs were also transduced, indicating vector spread from the injected muscle to both the CNS and the periphery through release into the blood circulation. Moreover, we showed that i.m. injection of scAAV9 vectors expressing “survival of motor neuron” (Smn) in spinal muscular atrophy (SMA) mice mediated high survival motor neuron (SMN) expression levels at both the CNS and the periphery, and increased the median lifespan from 12 days to 163 days. These findings represent to date the longest extent in survival obtained in SMA mice following i.m. viral vector gene delivery, and might generate a renewed interest in the use of i.m. adeno-associated viruses (AAV) delivery for the development of gene therapy strategies for MN diseases. We have recently demonstrated the remarkable efficiency of self-complementary (sc) AAV9 vectors for central nervous system (CNS) gene transfer following intravenous delivery in mice and larger animals. Here, we investigated whether gene delivery to motor neurons (MNs) could also be achieved via intramuscular (i.m.) scAAV9 injection and subsequent retrograde transport along the MNs axons. Unexpectedly, we found that a single injection of scAAV9 into the adult mouse gastrocnemius (GA) mediated widespread MN transduction along the whole spinal cord, without limitation to the MNs connected to the injected muscle. Spinal cord astrocytes and peripheral organs were also transduced, indicating vector spread from the injected muscle to both the CNS and the periphery through release into the blood circulation. Moreover, we showed that i.m. injection of scAAV9 vectors expressing “survival of motor neuron” (Smn) in spinal muscular atrophy (SMA) mice mediated high survival motor neuron (SMN) expression levels at both the CNS and the periphery, and increased the median lifespan from 12 days to 163 days. These findings represent to date the longest extent in survival obtained in SMA mice following i.m. viral vector gene delivery, and might generate a renewed interest in the use of i.m. adeno-associated viruses (AAV) delivery for the development of gene therapy strategies for MN diseases.
43
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust, Emily Nurre, Chrystal L. Montgomery et al. · Nature Biotechnology · 2008 · 1.4K citations · Full text
Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model
Brian K. Kaspar, Jerònia Lladó, Nushin Sherkat et al. · Science · 2003 · 867 citations
A mouse model for spinal muscular atrophy
Hsiu Mei Hsieh‐Li, Jan‐Gowth Chang, Yuh‐Jyh Jong et al. · Nature Genetics · 2000 · 710 citations
Medicine, Neurobiology, Neuroscience +11